OBJECTIVES: The purpose of this study was to compare the clinical outcomes of induction chemoradiotherapy and chemotherapy and to identify the prognostic factors for non-small-cell lung cancer patients with mediastinal lymph node metastasis who were treated with induction therapy. METHODS: Between August 1995 and December 2010, 50 non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis were scheduled to receive induction therapy followed by surgery. Irinotecan plus cisplatin was used for induction chemotherapy from June 1995 to April 1999, and docetaxel plus cisplatin with concurrent radiation at a dose of 40-46 Gy has been used for induction chemoradiotherapy since May 1999. RESULTS: Thirty-five patients were treated with induction chemoradiotherapy and 15 were treated with induction chemotherapy. For the entire population, the 3-year and 5-year overall survival rates were 64.1 and 53.9%, respectively, and the 1-year and 2-year disease-free survival rates were 70.0 and 53.1%, respectively. Among the clinicopathological factors, the chemoradiotherapy group exhibited longer overall survival and disease-free survival than the chemotherapy group (overall survival, P = 0.0020; disease-free survival, P = 0.015). Pathological downstaging was also significantly associated with favorable overall survival (P = 0.0042) and disease-free survival (P = 0.021). A multivariate analysis showed that chemoradiotherapy (P = 0.0099) and pathological downstaging (P = 0.039) were independent prognostic factors. CONCLUSIONS: Our results indicated that induction chemoradiotherapy was superior to induction chemotherapy with regard to the outcome of non-small-cell lung cancer patients with mediastinal lymph node metastasis.
OBJECTIVES: The purpose of this study was to compare the clinical outcomes of induction chemoradiotherapy and chemotherapy and to identify the prognostic factors for non-small-cell lung cancerpatients with mediastinal lymph node metastasis who were treated with induction therapy. METHODS: Between August 1995 and December 2010, 50 non-small-cell lung cancerpatients with pathological mediastinal lymph node metastasis were scheduled to receive induction therapy followed by surgery. Irinotecan plus cisplatin was used for induction chemotherapy from June 1995 to April 1999, and docetaxel plus cisplatin with concurrent radiation at a dose of 40-46 Gy has been used for induction chemoradiotherapy since May 1999. RESULTS: Thirty-five patients were treated with induction chemoradiotherapy and 15 were treated with induction chemotherapy. For the entire population, the 3-year and 5-year overall survival rates were 64.1 and 53.9%, respectively, and the 1-year and 2-year disease-free survival rates were 70.0 and 53.1%, respectively. Among the clinicopathological factors, the chemoradiotherapy group exhibited longer overall survival and disease-free survival than the chemotherapy group (overall survival, P = 0.0020; disease-free survival, P = 0.015). Pathological downstaging was also significantly associated with favorable overall survival (P = 0.0042) and disease-free survival (P = 0.021). A multivariate analysis showed that chemoradiotherapy (P = 0.0099) and pathological downstaging (P = 0.039) were independent prognostic factors. CONCLUSIONS: Our results indicated that induction chemoradiotherapy was superior to induction chemotherapy with regard to the outcome of non-small-cell lung cancerpatients with mediastinal lymph node metastasis.
Authors: Michael T Jaklitsch; James E Herndon; Malcolm M DeCamp; William G Richards; Parvesh Kumar; Mark J Krasna; Mark R Green; David J Sugarbaker Journal: J Surg Oncol Date: 2006-12-01 Impact factor: 3.454
Authors: W Eberhardt; H Wilke; G Stamatis; M Stuschke; A Harstrick; H Menker; B Krause; M R Müeller; M Stahl; M Flasshove; V Budach; D Greschuchna; N Konietzko; H Sack; S Seeber Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: K S Albain; V W Rusch; J J Crowley; T W Rice; A T Turrisi; J K Weick; V A Lonchyna; C A Presant; R J McKenna; D R Gandara Journal: J Clin Oncol Date: 1995-08 Impact factor: 44.544
Authors: H Katayama; H Ueoka; K Kiura; M Tabata; T Kozuki; M Tanimoto; T Fujiwara; N Tanaka; H Date; M Aoe; N Shimizu; M Takemoto; Y Hiraki Journal: Br J Cancer Date: 2004-03-08 Impact factor: 7.640
Authors: K Kiura; H Ueoka; Y Segawa; M Tabata; H Kamei; N Takigawa; S Hiraki; Y Watanabe; A Bessho; K Eguchi; N Okimoto; S Harita; M Takemoto; Y Hiraki; M Harada; M Tanimoto Journal: Br J Cancer Date: 2003-09-01 Impact factor: 7.640
Authors: Sai Yendamuri; Adrienne Groman; Austin Miller; Todd Demmy; Mark Hennon; Elisabeth Dexter; Anthony Picone; Chukwumere Nwogu; Grace K Dy Journal: Eur J Cardiothorac Surg Date: 2018-03-01 Impact factor: 4.191